Key result
Iberiotoxin attenuates tumorigenicity in HER-2/neu and triple-negative breast cancer cells via β-catenin downregulation.
Why the study?
Does iberiotoxin modulate the tumorigenic ability of hormone-independent breast cancer cells?
Does iberiotoxin modulate the tumorigenic ability of hormone-independent breast cancer cells?
p-value: p=≤0.05
Iberiotoxin attenuates anchorage-independent growth in sensitive hormone-independent breast cancer cells, identifying β-catenin as a putative modulator of its inhibitory actions.
In breast cancers, the large conductance Ca2+ and voltage sensitive K+ (BKCa) channels have been hypothesized to function as oncoproteins, yet it remains unclear how inhibition of channel activity impacts oncogenesis. We demonstrated herein that iberiotoxin (IbTX), an inhibitor of BKCa channels, differentially modulated the in vitro tumorigenic activities of hormone-independent breast cancer cells. Specifically, in HER-2/neu-overexpressing UACC893 cells and triple‑negative MDA-MB-231 cells, IbTX selectively attenuated anchorage-independent growth with concomitant downregulation of β-catenin as well as total and phosphorylated Akt and HER-2/neu. By contrast, HER-2/neu-overexpressing SK-BR-3 cells were insensitive to IbTX. Molecular analyses showed an absence of β-catenin and a dose-dependent upregulation of total and phosphorylated Akt and HER-2/neu in these cells. Taken together, these studies identify β-catenin as a putative modulator of the inhibitory actions of IbTX in sensitive breast cancer cells.
No takes yet. Share an insight, caveat, or question.
Schickling et al. (2014) studied Hormone-independent breast cancer. Iberiotoxin (IbTX) vs. Untreated control was evaluated on Anchorage-independent growth and transmembrane potential (p=≤0.05). Iberiotoxin selectively attenuated anchorage-independent growth and tumorigenicity in HER-2/neu-overexpressing UACC893 and triple-negative MDA-MB-231 breast cancer cells via downregulation of β-catenin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: